December 2012 - Page 5 of 13

MondayDec 17, 2012 8:25 am

Rafarma Pharmaceuticals, Inc. (RAFA) Achieves Full Certification

Rafarma Pharmaceuticals announced that its manufacturing and packaging facility in Lipetsk, Russia was fully licensed last November 9th and exhibited by GMP ("Good Manufacturing Practices") Certificate # 109489 7000-430 (see: http://rafarma.com). The facility is ISO 9001 and IHC Q 10 compliant. These internationally recognized certifications allow sales and distribution of all permitted products throughout Europe and all nations that are a party to the above standards. The manufacturing facility is currently operating at 30% capacity during its "start-up" phase, and is expected to reach full production during the second quarter of 2013. With the resignation of Vladimir Bondar as Director…

MondayDec 17, 2012 7:37 am

Integrated Electrical Services, Inc. (IESC) Reports Fiscal 2012 Fourth Quarter and Year-End Results

Integrated Electrical Services, an infrastructure services company with leading positions in a broad range of markets for electrical and communications products and services, announced financial results for its fiscal 2012 fourth quarter and year ended September 30, 2012. James Lindstrom, Chairman and Chief Executive Officer, stated, “We are pleased with the performance improvement of IES in 2012. Our employees’ ownership mindset and their sharpened focus on delivering superior performance in our core fields of expertise has led to another quarter of revenue growth, margin improvement and increased backlog. We are poised to continue with and build upon the operational improvements…

MondayDec 17, 2012 7:36 am

InVivo Therapeutics Holdings Corp. (NVIV) Requests Humanitarian Use Device Designation

InVivo Therapeutics, a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, announced that it has pursued a Humanitarian Use Device (HUD) designation for its biopolymer scaffolding product by filing a request with the U.S. Food and Drug Administration (FDA). The company is currently in works with the FDA to finalize the approval process and begin clinical trial of the scaffolding acute SCI in early 2013. Humanitarian Use Devices, commonly referred to as HUDs, are developed to treat rare diseases or conditions. InVivo seeks to obtain this designation for its biopolymer scaffolding for…

MondayDec 17, 2012 7:36 am

Fibrocell Science, Inc. (FCSC) Video Chart for Monday, December 17, 2012

FCSC is making a double bottom pattern with support at 14 cents. The last move off this level set resistance at 24 cents. A small climb on Friday, combined with indicators giving hints of potential upward pressure, puts the chart on radar. To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts Let us hear your thoughts below:

MondayDec 17, 2012 7:35 am

Energy 1 Corp. (EGOC) Spammed Aggressively

We have observed an influx of emails spamming Energy 1. Investors should be wary of these emails, as they are completely anonymous and violate the CAN-SPAM Act established by the FTC. As of this time, the company has not provided a public comment on the issue. Stocks to avoid, due diligence, monitoring investments, key terms in investing and other related topics are covered by us in our Market Basics section. Here we give answers to basic questions regarding stock investments for both new and experienced investors. To view our Market Basics page, visit www.basics.qualitystocks.net. QualityStocks also helps protect investors by…

FridayDec 14, 2012 2:13 pm

Amarantus BioScience, Inc. (AMBS) Licenses Memory Dx LymPro Alzheimer’s Diagnostic Test

Amarantus BioScience has licensed the LymPro Alzheimer’s Disease Diagnostic Blood Test from Memory Dx LLC (MDx), growing Amarantus’ existing diagnostic pipeline and positioning the company to participate in related future opportunities. LymPro, designed to diagnose Alzheimer’s in its mild to moderate stage, has completed two phase 1 clinical studies and is ready to move into a phase 2 validation study. If successful, Amarantus anticipates that LymPro can begin generating revenue as a laboratory-developed test within 18 months of study initiation, through commercial sales and sales to companies performing Alzheimer’s disease clinical research. “We believe LymPro has significant clinical and commercial…

FridayDec 14, 2012 2:13 pm

The CHMP Renders a Positive Opinion Recommending Approval of Marketing Authorization for Alexza Pharmaceuticals, Inc. (ALXA) Product in the EU

Alexza Pharmaceuticals and Grupo Ferrer Interncional, S.A., announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending that ADASUVE (Staccato loxapine) be granted European Union (EU) centralized marketing authorization. The CHMP recommends that ADASUVE be authorized in the EU for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. The recommendation by the CHMP is that ADASUVE should be administered only in a hospital setting under the supervision of a healthcare professional. Short-acting beta-agonist bronchodilator treatment should be available for treatment of…

FridayDec 14, 2012 2:11 pm

Joseph M. Limber Appointed to XOMA Corp. (XOMA) Board of Directors

XOMA, a leader in the discovery and development of therapeutic antibodies, announced that Mr. Joseph M. Limber has been appointed to its Board of Directors. “I am pleased to welcome Joe to our Board of Directors,” remarked John Varian, XOMA’s Chief Executive Officer. “Our team is particularly excited to work closely with Joe, as he has successfully developed markets for specialty pharmaceutical products and managed the critical transition from research organization to commercial entity. We expect to make the same transition in the coming years and Joe’s insight and guidance while we prepare for a gevokizumab commercial launch will be…

ThursdayDec 13, 2012 2:40 pm

Lithium Corp. (LTUM) Positive Drilling Results on San Emidio Validate Lithium Resource Model, Company Plans Deeper Drilling

Lithium Corp. is reporting good news today, as the analytical results come in from the most recent round of drilling at their San Emidio site in Nevada, showing peak value returns as high as 23.7 mg/l lithium in the previously identified, lithium-in-brine anomaly (values 10 to 20 times the background levels outside the anomaly). The some 1,600-acre block of claims that makes up the San Emidio playa prospect in northwestern Nevada’s lithium-rich Washoe county are starting to look extremely appealing to LTUM as one of their most exciting properties. This most recent drilling’s ability to further delineate the targeted anomaly…

ThursdayDec 13, 2012 2:39 pm

StrikeForce Technologies, Inc. (SFOR) Addresses Increasing Cyber Threats with New Anti-Breach Cyber Security Bundle

StrikeForce Technologies, developer of keystroke encryption technology that prevents keylogger malware from stealing sensitive information and passwords, today unveiled its new comprehensive Anti-Breach Cyber Security bundle. According to a year-over-year comparison of the Ponemon Institute’s studies of cyber-attacks among select companies, the number of cyber-attacks increased 42 percent in 2012 vs. 2011. In the 2012 Crime Study, Ponemon reported 102 successful attacks per week in 2012, as compared to 72 successful attacks on average per week in 2011. The 2011 attacks cost 56 organizations in this study an annual average of $8.9 million per year, with costs ranging between $1.4…

Site Search

Company Search

Month: December 2012